Christophe Lahorte - Head of Scientific-Technical Advice & KM unit, famhp
Short description of the presentation:
The famhp will implement in 2017 a national Innovation Office in order to support, accelerate and promote the research and development of new innovative drug and healthcare products in Belgium to the benefit of the patient. The presentation will focus on the future role and importance of the national Innovation Office which will serve as an easy and central access point (eg. for local SME’s, spin-offs, academic research centres, other innovators) to the regulatory and scientific expertise of the famhp. Furthermore, the interaction mechanisms with the European Innovation Offices Network will be explained.
Biography of the speaker:
Christophe Lahorte holds a master degree in pharmaceutical sciences and has performed academic research for 6 years at the Gent University (Faculty of Pharmacy, Laboratory of Radiopharmacy) where he was responsible for the chemical-pharmaceutical and (pre)clinical development of new radiopharmaceuticals in collaboration with the Nuclear Medicine Dept. of the University hospital Gent (UZG). He obtained a PhD in Pharmaceutical Sciences at the University of Gent in 2004 after which he moved to the Federal Public Health services as a quality assessor. At that time Christophe Lahorte was temporarily member of the CHMP Quality Working Party. Since September 2004 he has been actively involved within the R&D department of the famhp in the quality assessment of clinical trial applications (CTA’s) and paediatric investigation plans (PIP’s). Since 2006 he has also been involved in the assessment of several national and European scientific advice requests. As of 2009 he’s the head of the unit for National Scientific-Technical Advice & Knowledge Management within the Directorate General pre authorisation. In addition, he is a member of the EU Innovation Offices Network coordinated by the European Medicines Agency and currently active as project coordinator within the famhp for the implementation of the “National Innovation Office”.